Suprachoroidal Administration in Subjects With Metastases to the Choroid

Recruiting now · Phase 2

Conditions studied: Eye Cancer, Primary Cancer

In brief

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.

Key facts

Study ID: NCT06643884
Run by: Aura Biosciences
People needed: 24
Starts: 2024-12-16
Expected to finish: 2027-10-31
Last updated by the study team: 2026-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.
Have at least one Metastases to the Choroid in the study eye

You may not qualify if…

Active ocular infection or disease.
Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.
Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment

Where it is running

Byers Eye Institute at Stanford University — Palo Alto, California, United States (enrolling)
Bascom Palmer Eye Institute — Miami, Florida, United States (enrolling)
Massachusetts Eye and Ear — Boston, Massachusetts, United States (enrolling)
Kellogg Eye Center — Ann Arbor, Michigan, United States (enrolling)
Tennessee Retina, PC — Nashville, Tennessee, United States (enrolling)
Retina Consultants of Texas — Bellaire, Texas, United States (enrolling)
University of Washington — Seattle, Washington, United States (enrolling)
Mayo Clinic — Rochester, Minnesota, United States
Cleveland Clinic, Cole Eye Institute — Cleveland, Ohio, United States
Shields and Shields, PC — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.